A collaboration between Qkine and 3D Bio-Tissues has been awarded one of four prestigious prizes at the 2022 EIT Food Venture Summit, held in Lisbon, Portugal. Prize money will be used to develop new solutions to reduce the cost of cultivated meat.
Qkine secure a new lease on premises based in Cambridge city centre. The building will be transformed into modern agile lab and office spaces for research and process development, plus a dedicated, beta lactam free state of the art manufacturing suite.
Despite the ongoing challenges faced by the whole industry, we are demonstrating our commitment to supporting stem cell researchers by freezing our prices until January 1st, 2023. Furthermore, we will include free shipping on all orders moving forward.
Qkine certified ISO9001: 2015 for its quality management system encompassing R&D, manufacturing, and operations in Cambridge, UK. Qkine supplies growth factors and cytokines to the fast-moving stem cell, organoid and emerging cultured meat sectors. Exceptional product quality and scientific support are crucial to customer's business processes and experimental outcomes.
Qkine and Enantis have concluded a global licensing deal for Enantis’s patented FGF2-STAB® technology. FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. FGF2-STAB (FGF2-G3) does not degrade in culture media for enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.
Cambridge, UK 21 July 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – is delighted to announce the appointment of Rob Nixon to its management team as Head of Commercial and Dr Cassie Doherty, Investment Director at Parkwalk, to its board. With years of [...]
Qkine secures £1.5M series A funding from leading life science investors Cambridge, UK 08 June 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – today announced the successful closure of a £1.5M series A investment round to accelerate the global [...]
Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio Cambridge, UK 03 June 2019: Qkine, specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applications, has closed a further round of investment. The £550K funding round was led by Cambridge Enterprise [...]
Qkine backed by Cambridge Enterprise and a quintet of angels University of Cambridge spin-out Qkine has closed its seed investment round supported by Cambridge Enterprise, the commercialisation arm of the University, and a team of five angels led by Jim Warwick. The amount is undisclosed. Qkine is a specialist manufacturer [...]
© 2024 Qkine Ltd. Company number 10470662 registered in England and Wales. All rights reserved
